Fluxion Therapeutics
Fluxion Therapeutics is focused on advancing pre-clinical drug discovery by integrating real-time electrophysiology data with artificial intelligence for the analysis of ion channel activity. The company specializes in large-scale electrophysiological data collection, automated patch-clamp analytics, and the development of machine learning models for drug safety and toxicology. Its mission is to unlock dynamic, functional insights from live cell signals, offering a new 'omics' layer for cellular physiology in drug R&D.
Industries
N/A
Products
A software toolset supporting automated quality control, analytics, and feature extraction from patch-clamp ion channel electrophysiology data, compatible with high-throughput and manual datasets.
A set of tools for developing, validating, and interpreting high-throughput ion channel and safety assays using machine learning models integrated with omics data.
A software toolset supporting automated quality control, analytics, and feature extraction from patch-clamp ion channel electrophysiology data, compatible with high-throughput and manual datasets.
A set of tools for developing, validating, and interpreting high-throughput ion channel and safety assays using machine learning models integrated with omics data.
Services
Analysis and quality control of automated and manual patch-clamp data using machine learning-based workflows, including parameter extraction and visualization across multiple platforms.
Provision of predictive analytics for cardiotoxicity, hepatotoxicity, and immunotoxicity using AI-driven models validated on large screening datasets.
Analysis and quality control of automated and manual patch-clamp data using machine learning-based workflows, including parameter extraction and visualization across multiple platforms.
Provision of predictive analytics for cardiotoxicity, hepatotoxicity, and immunotoxicity using AI-driven models validated on large screening datasets.
Expertise Areas
- AI-driven electrophysiology analytics
- Ion channel drug discovery
- Predictive toxicology modeling
- High-throughput screening data analysis
Key Technologies
- Artificial intelligence for life sciences
- Automated patch-clamp electrophysiology
- Machine learning models
- High-throughput screening platforms
Key People
News & Updates
Vince Groppi, Ph.D., with over 30 years of neuroscience drug discovery and assay development experience, joins the Scientific Advisory Board to guide strategic development of AI-driven electrophysiology analytics platforms.
The company has entered a two-year collaboration with the University of Michigan’s CCG to develop AI/ML models for automated ion channel electrophysiology analysis, emphasizing predictive safety and toxicology.
Vince Groppi, Ph.D., with over 30 years of neuroscience drug discovery and assay development experience, joins the Scientific Advisory Board to guide strategic development of AI-driven electrophysiology analytics platforms.
The company has entered a two-year collaboration with the University of Michigan’s CCG to develop AI/ML models for automated ion channel electrophysiology analysis, emphasizing predictive safety and toxicology.